CFO David Benedicto resigns; President/COO Marguglio named interim CFO

DMK PHARMACEUTICALS Corp

David C. Benedicto resigned as CFO and principal accounting officer, effective July 21, 2023.
Resignation not due to any disagreement with the company or auditors on financial matters.
David J. Marguglio, President and COO, appointed interim CFO while a permanent replacement is sought.
Marguglio has been with Adamis since 2009 and previously served as CEO until the DMK merger in May 2023.
Company will commence a search for a new CFO; no formal arrangement or understanding with Mr. Marguglio.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

David C. Benedicto

chief financial officer and principal accounting officer

DMK PHARMACEUTICALS Corp

Effective: 2023-07-21
Successor: David J. Marguglio
Filed: July 24, 2023, 7:59 PM ET

On July 18, 2023, David C. Benedicto, the chief financial officer and principal accounting officer of Adamis Pharmaceuticals Corporation (the “Company”), notified the Company that he was tendering his resignation from the Company effective July 21, 2023.

Appointed (interim)

David J. Marguglio

interim chief financial officer

DMK PHARMACEUTICALS Corp

Filed: July 24, 2023, 7:59 PM ET

In the interim, David J. Marguglio, the Company’s President and Chief Operating Officer, will assume the duties of chief financial officer of the Company on an interim basis until the Company appoints a successor, and the board of directors of the Company has approved that appointment.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David C. Benedicto resigned as chief financial officer and principal accounting officer at DMK PHARMACEUTICALS Corp.

Action: resigned
Role: chief financial officer and principal accounting officer

Exact text from the filing

On July 18, 2023, David C. Benedicto, the chief financial officer and principal accounting officer of Adamis Pharmaceuticals Corporation (the “Company”), notified the Company that he was tendering his resignation from the Company effective July 21, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David J. Marguglio was appointed as interim chief financial officer at DMK PHARMACEUTICALS Corp.

Action: appointed
Role: interim chief financial officer

Exact text from the filing

In the interim, David J. Marguglio, the Company’s President and Chief Operating Officer, will assume the duties of chief financial officer of the Company on an interim basis until the Company appoints a successor, and the board of directors of the Company has approved that appointment.

View on SEC.gov

Source: SEC EDGAR

accession 0001387131-23-008595

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.